← All trials
NCT05466734
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2022
- Primary completion
- Aug 23, 2022
- Completion date
- Sep 30, 2022
- First posted
- Jul 20, 2022
- Last posted
- Aug 31, 2022
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Genovate Biotechnology Co., Ltd.,Lead sponsor
- Bio-Kinetic Clinical ApplicationsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.